Compare FOIL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Londian Wason New Energy Tech Inc. American Depositary Shares each representing five Ordinary Shares
Current Price
Current Price
| Metric | FOIL | ORIC |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2024 | 2020 |
| Metric | FOIL | ORIC |
|---|---|---|
| Price | $14.88 | $8.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 42.5K | ★ 1.9M |
| Earning Date | 12-23-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $68.57 | N/A |
| Revenue Next Year | $10.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.51 | $7.23 |
| 52 Week High | $25.47 | $14.68 |
| Indicator | FOIL | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 35.41 |
| Support Level | $12.51 | $7.62 |
| Resistance Level | $23.41 | $9.13 |
| Average True Range (ATR) | 1.53 | 0.97 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 28.11 | 6.15 |
Londian Wason New Energy Tech Inc is engaged in the research, development, and manufacture of electrolytic copper foil. Its product portfolio includes lithium-ion battery (LiB) copper foil, printed circuit board (PCB)-grade copper foil, and flexible copper clad laminates (FCCLs). Its products are used in applications including electric vehicles, energy storage systems, communication equipment, and consumer electronics. The company derives its revenue from contracts with customers, including the sales of LiB copper foil, PCB-grade copper foil and others in the PRC.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.